Podcast: Michael Kamarck of Merck BioVentures on Opportunities in Biosimilars

Published on: 

Opportunities in Biosimilars

Michael Kamarck, President, Merck BioVenturesOpportunities in Biosimilars

With the approval of an abbreviated pathway by which biosimilars may be authorized in the US, the attention is now shifting to the challenges in store for innovator companies in defending their patents and the generics companies in challenging them. In this interview, Michael Kamarck, president of Merck BioVentures and senior vice president, vaccines and biologics manufacturing, discusses the opportunities and challenges in biosimilars.